Lupus & antiphospholipid syndrome
Serum CXCL-13 levels are associated with active neurological involvement in patients with systemic lupus erythematosus
Authors' conclusion
This study underscores the association between serum CXCL-13 levels and neuropsychiatric involvement in SLE, as well as their correlation with disease activity.
Study context
- Population
- Systemic lupus erythematosus (SLE) patients with and without neuropsychiatric involvement and healthy controls
- Participants
- 125 patients
- Exposure
- Active NPSLE vs inactive NPSLE vs SLE without NPSLE vs healthy controls
- Active NPSLEn = 6
- Inactive NPSLEn = 26
- SLE without NPSLEn = 71
- Healthy controlsn = 22reference
- Outcome
- Serum CXCL-13 levels (Enzyme Linked ImmunoSorbent Assay (ELISA))
- Follow-up
- At enrollment
Main finding
As reported in the abstract
Serum CXCL-13 levels
- Significantly elevated CXCL-13 in active NPSLE vs other SLE groups and healthy controls
- Active NPSLE vs Inactive NPSLE: P < 0.001
- Active NPSLE vs SLE without NPSLE: P < 0.001
- Active NPSLE vs Healthy controls: P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Serum CXCL-13 in SLE (inactive NPSLE or no NPSLE history) vs controlsInactive NPSLE vs Healthy controls · significantly higher | P < 0.001 |
| Serum CXCL-13 in SLE (inactive NPSLE or no NPSLE history) vs controlsSLE without NPSLE vs Healthy controls · significantly higher | P < 0.001 |
Correlation of serum CXCL-13 with disease activity (Systemic Lupus Erythematosus Disease Activity Index (SLEDAI))
- Serum CXCL-13 positively correlated with SLEDAI
Original publication
Serum CXCL-13 levels are associated with active neurological involvement in patients with systemic lupus erythematosus. Lupus. Published 7 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →